RecruitingNCT07561424

Comparisons Of Biochemical And Clinical Outcomes Of Hemodialysis Patients Treated With Middle Cut-Off Dialyzers Versus High-Flux Hemodialysis Or Hemodiafiltration


Sponsor

Arbor Research Collaborative for Health

Enrollment

1,000 participants

Start Date

Feb 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The CONCORDIA study is a retrospective, observational study evaluating clinical and biochemical outcomes among patients receiving maintenance hemodialysis with medium cut-off (MCO) dialyzers (Theranova) compared with high-flux hemodialysis (HF-HD) and hemodiafiltration (HDF). Using real-world data from non-DOPPS Theranova sites and the DOPPS cohort as an external control, the study aims to assess whether MCO dialyzers are associated with improved outcomes versus HF-HD and non-inferior outcomes compared with HDF. The primary outcome is all-cause mortality, with secondary outcomes including cardiovascular events, hospitalizations, infections, and laboratory measures related to anemia, mineral metabolism, and inflammation.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • years of age or older
  • Treated at an in-centre dialysis clinic
  • Receiving chronic, maintenance HD

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

AURA

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07561424


Related Trials